Market evolution: Hormone drugs (CN 300439) — 2015–2025

Introduction

This report examines the evolution of EU extra-Union trade in CN 300439 — medicaments containing hormones or steroids used as hormones (excluding antibiotics, insulin, and corticosteroids) — over the period 2015–2025. The product scope covers a broad category of pharmaceutical preparations put up in measured doses or for retail sale, encompassing hormonal therapies for reproductive health, growth disorders, endocrine conditions, and other therapeutic uses.

Over the eleven-year period under review, the EU has undergone a dramatic expansion in this trade segment. Total export values rose from €6.5 billion in 2015 to over €24.2 billion in 2025, while import values climbed from €1.9 billion to over €6.0 billion. This growth reflects not only increasing global demand for hormonal medicaments but also the EU's consolidation as a leading producer and exporter of high-value pharmaceutical products. The analysis that follows unpacks three central dynamics: the scale and nature of this trade expansion, the evolving geography of EU trade partners, and the internal specialisation patterns across EU Member States.

1. An Explosive Expansion of Trade Driven by Value Rather Than Volume

EU exports have nearly quadrupled in value while volumes roughly doubled

The most striking feature of the 2015–2025 period is the sheer magnitude of growth in EU trade flows. As the table below shows, export values grew by 272.3%, far outpacing the 117.5% increase in export volumes. Import values rose by 211.0%, while import volumes grew by just 57.8%.

This divergence between value and volume growth is explained by a sustained increase in unit values. Export prices per tonne rose from €358,635 to €613,830 (+71.2%), while import prices climbed from €447,806 to €882,637 (+97.1%). The sharper rise in import unit values suggests that the EU is increasingly sourcing higher-priced — and potentially more specialised — hormonal products from abroad, even as it continues to dominate the export side with a massive and widening trade surplus.

The EU's trade surplus has expanded dramatically, reinforcing its role as a net exporter

The trade balance grew from €4.6 billion in 2015 to €18.2 billion in 2025 — an increase of 298.2%. This reflects the EU's strong comparative advantage in hormone drug manufacturing. Indeed, export propensity — exports as a share of domestic production — surged from 57.9% to 125.6%, indicating that by 2025, the EU was exporting more hormone drugs by value than it produced domestically, likely reflecting re-export activity and integrated supply chains. Meanwhile, the EU's net import reliance became deeply negative (from −60% to −23,139%), a mathematical artefact reflecting the dominance of exports over imports, but nonetheless confirming the EU's structural position as a net supplier to global markets.

EU domestic production has kept pace, reinforcing the export base

EU production values for CN 300439 rose from €6.4 billion to €16.9 billion (+164.2%). Although production data gaps exist for certain years, the trend clearly confirms that the export boom has been underpinned by genuine expansion of EU manufacturing capacity, not merely by trade intermediation. Trade intensity — the sum of imports and exports relative to production — grew from 65.0% to 120.3%, reflecting an increasingly outward-oriented sector.

2. A Rapidly Shifting Geography of Trade Partners

China has emerged as a major import source, while traditional partners have stagnated

The partner breakdown reveals a profound restructuring of the EU's import sources. China's share of EU imports surged from a negligible €0.65 million in 2015 to €2.04 billion in 2025 — an increase of over 311,000%. This is by far the most dramatic shift in the dataset and likely reflects the rapid scaling of Chinese active pharmaceutical ingredient (API) and finished-dose manufacturing, combined with EU demand for cost-competitive hormonal products.

Meanwhile, the United Kingdom — historically a significant supplier — saw EU imports decline by 39.3%, a trend likely linked to post-Brexit regulatory divergence and supply chain reconfiguration. India also saw a sharp decline of 80.2%, potentially reflecting a shift of manufacturing activity to China or stricter EU quality controls. Switzerland remained a stable and significant partner (+58.6%), consistent with its role as a hub for major pharmaceutical companies.

The rise of "unspecified origins" (from €0.3 million to €808 million) deserves attention. This category, used when the true origin is not declared for commercial or military reasons, suggests growing use of complex, multi-jurisdiction supply chains or confidentiality arrangements in the pharmaceutical sector.

Export markets have broadened, with the United States and United Kingdom leading growth

On the export side, the United States remained the EU's largest single destination, growing from €1.02 billion to €9.01 billion (+783.6%). The United Kingdom saw even faster growth in proportional terms, rising from €457 million to €4.64 billion (+914.6%), suggesting that despite Brexit, the UK remains a critical market for EU pharmaceutical exports — possibly because many EU-based manufacturers have subsidiaries or distribution centres in the UK.

Notable is the emergence of Saudi Arabia as a fast-growing destination (+838.2%), reflecting broader trends in Middle Eastern healthcare investment and demand for specialty pharmaceuticals. China also features prominently on the export side (+390.2%), highlighting the bidirectional nature of EU-China pharmaceutical trade: the EU both sources and supplies hormone drugs to the Chinese market.

Trade concentration has modestly increased on both sides

The Herfindahl-Hirschman Index (HHI) for import concentration (by value) rose from 2,872 to 3,165 (+10.2%), while export concentration increased from 1,527 to 1,932 (+26.5%). Although both remain below the threshold typically associated with high concentration (2,500), the upward trend in exports suggests a growing reliance on a smaller number of key destination markets — particularly the US and UK. By volume, import concentration actually declined (−24.7%), suggesting that while the value of imports from a few partners (notably China) has surged, the physical volumes remain more evenly distributed.

3. Uneven Specialisation and Volatility Across EU Member States

Italy, France, and Spain have emerged as the EU's export powerhouses

The Member State breakdown reveals striking differences in national performance. Italy saw the largest absolute growth, with exports rising from €1.09 billion to €8.70 billion (+697.8%), cementing its position as the EU's leading exporter of hormone drugs by 2025. Spain experienced the most dramatic relative growth, with exports surging from just €70 million to €2.13 billion (+2,946%), suggesting rapid capacity expansion or the establishment of major production facilities during the period.

Austria is the notable exception, with exports declining by 41.3% — a significant contraction that may reflect shifting production geographies or the loss of competitive advantage in specific product sub-segments.

On the import side, France saw the most dramatic increase (+788.2%), followed by Denmark (+2,267%). The Netherlands remained the EU's largest single import gateway, consistent with its role as a major logistics and distribution hub for pharmaceuticals entering the EU.

Specialisation patterns confirm Italy and France as the EU's hormone drug champions

The revealed symmetric comparative advantage (RSCA) data for 2025 shows that Italy (RSCA: 0.73, RCA: 6.29) and France (RSCA: 0.42, RCA: 2.48) are by far the most specialised EU Member States in CN 300439. Italy alone accounts for 50.4% of EU production in this product category, while France contributes 19.3%. Together, these two countries dominate the EU's competitive position in global hormone drug markets.

At the other end, Luxembourg (RSCA: −0.94), Finland (−0.93), Estonia (−0.92), and Poland (−0.91) show strong negative specialisation, meaning they are heavily reliant on imports for their hormone drug consumption relative to their overall trade profile.

Price volatility has been concentrated in emerging-market supply relationships

The volatility analysis reveals that import volatility has been highest for emerging and non-traditional partners. India (CV: 1.60), Singapore (CV: 1.46), and China (CV: 1.25) show the highest coefficients of variation in EU import values, indicating large year-to-year swings. By contrast, Switzerland (CV: 0.15) and Japan (CV: 0.20) have been remarkably stable suppliers, consistent with their established pharmaceutical industries and long-standing trade relationships with the EU.

On the export side, volatility to the United States (CV: 0.73) and Saudi Arabia (CV: 0.91) has been relatively high, while exports to Switzerland (CV: 0.14) and Russia (CV: 0.16) have been more predictable.

The supply shock analysis identifies three notable price shock events:

• Nigeria (exports, 2019): A price shock with an abnormality score of 23.8 and a 196.2% price shift, though the value share was minimal (0.1%), suggesting a one-off shipment of specialised products.
• Vietnam (exports, 2022): A 310.2% price shift with an abnormality of 18.8, possibly linked to pandemic-era supply chain disruptions or emergency procurement.
• Switzerland (exports, 2020): An 87.7% price shift affecting 25.8% of export value — the most significant shock event in terms of economic impact, likely reflecting COVID-19-related disruptions to pharmaceutical trade flows.

Conclusion

The EU's trade in hormone drugs (CN 300439) has undergone a remarkable transformation between 2015 and 2025. Export values have nearly quadrupled, the trade surplus has widened to over €18 billion, and the EU has consolidated its position as the world's dominant supplier of these high-value pharmaceutical products. This growth has been driven not merely by increasing volumes but significantly by rising unit values, reflecting the EU's position at the premium end of the global pharmaceutical market.

The geographic landscape of trade has shifted dramatically. China has emerged from near-irrelevance to become the EU's largest single import source, while the United States and United Kingdom have absorbed the bulk of export growth. These shifts underscore the increasingly global and interdependent nature of pharmaceutical supply chains, as well as the strategic importance of maintaining competitive production capacity within the EU.

At the Member State level, Italy and France stand out as the engines of the EU's competitive advantage, while Spain's explosive export growth suggests a new centre of production is emerging. However, the growing concentration of exports in a few key markets, combined with persistently high import volatility from emerging sources, points to potential vulnerabilities that policymakers may wish to monitor as the sector continues to evolve.